KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Novavax (NVAX) Interest & Investment Income (2016 - 2021)

Historic Interest & Investment Income for Novavax (NVAX) over the last 13 years, with Q4 2021 value amounting to $303000.0.

  • Novavax's Interest & Investment Income rose 11338.03% to $303000.0 in Q4 2021 from the same period last year, while for Dec 2021 it was $1.4 million, marking a year-over-year increase of 3438.42%. This contributed to the annual value of $1.4 million for FY2021, which is 3451.68% up from last year.
  • According to the latest figures from Q4 2021, Novavax's Interest & Investment Income is $303000.0, which was up 11338.03% from $330000.0 recorded in Q3 2021.
  • Novavax's 5-year Interest & Investment Income high stood at $807000.0 for Q2 2018, and its period low was $140000.0 during Q3 2020.
  • Moreover, its 5-year median value for Interest & Investment Income was $419000.0 (2017), whereas its average is $425550.0.
  • Its Interest & Investment Income has fluctuated over the past 5 years, first tumbled by 5906.43% in 2020, then skyrocketed by 13571.43% in 2021.
  • Quarter analysis of 5 years shows Novavax's Interest & Investment Income stood at $418000.0 in 2017, then soared by 39.71% to $584000.0 in 2018, then plummeted by 52.74% to $276000.0 in 2019, then tumbled by 48.55% to $142000.0 in 2020, then soared by 113.38% to $303000.0 in 2021.
  • Its Interest & Investment Income was $303000.0 in Q4 2021, compared to $330000.0 in Q3 2021 and $369000.0 in Q2 2021.